Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$105.03
-1.02-0.96%
À la fermeture: -
$105.50
0.470.45%
Après les heures de négociation: 6:21 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
BioNTech SE a un objectif de cours consensus de $137.39, basé sur les évaluations des 20 analystes. Le plus élevé est de $171.44 attribué par Canaccord Genuity le mars 11, 2025, et le plus bas est de $110 attribué par Goldman Sachs le mai 29, 2025. Les 3 dernières évaluations d'analystes ont été publiées par JP Morgan, Morgan Stanley et JP Morgan le octobre 23, 2025, octobre 10, 2025 et septembre 22, 2025. Avec un objectif de cours moyen de $124 entre JP Morgan, Morgan Stanley et JP Morgan, il y a une variation implicite de 17.54% upside pour BioNTech SE à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
JP Morgan
Morgan Stanley
HC Wainwright & Co.
Wells Fargo
B of A Securities
1calculé à partir des notes des analystes
Notes d'analystes pour BioNTech
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/23/2025 | 13.74% | JP Morgan | $121 → $120 | Maintains | Neutral | |||
10/10/2025 | 24.17% | Morgan Stanley | $133 → $131 | Maintains | Overweight | |||
09/22/2025 | 14.69% | JP Morgan | $116 → $121 | Maintains | Neutral | |||
09/08/2025 | 28.91% | HC Wainwright & Co. | $136 → $136 | Reiterates | Buy → Buy | |||
08/14/2025 | 28.91% | HC Wainwright & Co. | $138 → $136 | Maintains | Buy | |||
08/05/2025 | 42.18% | Wells Fargo | $170 → $150 | Maintains | Overweight | |||
08/05/2025 | 27.01% | B of A Securities | $126 → $134 | Maintains | Buy | |||
07/16/2025 | 19.43% | B of A Securities | $127 → $126 | Maintains | Buy | |||
07/10/2025 | 26.07% | Morgan Stanley | $132 → $133 | Maintains | Overweight | |||
06/25/2025 | 30.81% | HC Wainwright & Co. | $138 → $138 | Reiterates | Buy → Buy | |||
06/16/2025 | 30.81% | HC Wainwright & Co. | $145 → $138 | Maintains | Buy | |||
06/05/2025 | 37.44% | HC Wainwright & Co. | $134 → $145 | Maintains | Buy | |||
06/03/2025 | 46.92% | Truist Securities | $151 → $155 | Reiterates | Buy → Buy | |||
05/29/2025 | 4.27% | Goldman Sachs | → $110 | Initiates | → Neutral | |||
05/22/2025 | 9.95% | JP Morgan | $120 → $116 | Maintains | Neutral | |||
05/22/2025 | 27.01% | HC Wainwright & Co. | $134 → $134 | Reiterates | Buy → Buy | |||
05/14/2025 | 27.01% | HC Wainwright & Co. | $145 → $134 | Maintains | Buy | |||
05/06/2025 | 32.7% | Citigroup | $145 → $140 | Maintains | Buy | |||
05/06/2025 | 25.12% | Morgan Stanley | $140 → $132 | Maintains | Overweight | |||
04/01/2025 | 37.44% | HC Wainwright & Co. | $150 → $145 | Maintains | Buy | |||
03/13/2025 | 37.44% | Citigroup | → $145 | Initiates | → Buy | |||
03/11/2025 | 43.13% | Truist Securities | $172 → $151 | Maintains | Buy | |||
03/11/2025 | 31.75% | Morgan Stanley | $145 → $139 | Maintains | Overweight | |||
03/11/2025 | 62.5% | Canaccord Genuity | $171.44 → $171.44 | Maintains | Buy | |||
03/11/2025 | 35.55% | BMO Capital | $130 → $143 | Maintains | Outperform | |||
01/27/2025 | 13.74% | JP Morgan | $122 → $120 | Maintains | Neutral | |||
01/10/2025 | 63.03% | Truist Securities | → $172 | Initiates | → Buy | |||
12/11/2024 | 61.14% | Wells Fargo | → $170 | Initiates | → Overweight | |||
11/27/2024 | 62.5% | Canaccord Genuity | $171 → $171.44 | Maintains | Buy | |||
11/26/2024 | 15.64% | JP Morgan | $124 → $122 | Maintains | Neutral | |||
11/19/2024 | 18.48% | Evercore ISI Group | $110 → $125 | Upgrade | In-Line → Outperform | |||
11/18/2024 | 62.09% | Canaccord Genuity | $171 → $171 | Maintains | Buy | |||
11/18/2024 | 42.18% | HC Wainwright & Co. | $150 → $150 | Reiterates | Buy → Buy | |||
11/14/2024 | 62.09% | Canaccord Genuity | $171 → $171 | Maintains | Buy | |||
11/08/2024 | 29.86% | Goldman Sachs | $90 → $137 | Upgrade | Neutral → Buy | |||
11/06/2024 | 15.64% | TD Cowen | $132 → $122 | Maintains | Hold | |||
11/05/2024 | 15.64% | TD Cowen | $132 → $122 | Maintains | Hold | |||
11/04/2024 | 17.54% | JP Morgan | $125 → $124 | Maintains | Neutral | |||
10/07/2024 | 28.91% | HSBC | $97 → $136 | Maintains | Buy | |||
10/07/2024 | 42.18% | HC Wainwright & Co. | $113 → $150 | Maintains | Buy | |||
09/24/2024 | 37.44% | Morgan Stanley | $93 → $145 | Upgrade | Equal-Weight → Overweight | |||
09/19/2024 | 42.18% | Deutsche Bank | $95 → $150 | Maintains | Buy | |||
09/18/2024 | 24.17% | UBS | $97 → $131 | Maintains | Neutral | |||
09/17/2024 | 42.18% | Jefferies | $96 → $150 | Upgrade | Hold → Buy | |||
09/16/2024 | 18.48% | JP Morgan | $91 → $125 | Upgrade | Underweight → Neutral | |||
09/16/2024 | 42.18% | B of A Securities | $125 → $150 | Maintains | Buy | |||
09/16/2024 | 7.11% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
09/13/2024 | -9% | Jefferies | $90 → $96 | Maintains | Hold | |||
08/27/2024 | 7.11% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
08/19/2024 | 7.11% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
08/15/2024 | -13.74% | JP Morgan | $94 → $91 | Maintains | Underweight | |||
08/07/2024 | -9.95% | Deutsche Bank | $95 → $95 | Upgrade | Hold → Buy | |||
08/06/2024 | -19.43% | TD Cowen | $98 → $85 | Maintains | Hold | |||
08/01/2024 | 7.11% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
06/26/2024 | 7.11% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
06/12/2024 | -10.9% | JP Morgan | $90 → $94 | Maintains | Underweight | |||
06/10/2024 | 7.11% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
06/04/2024 | 7.11% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
06/03/2024 | 7.11% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
05/30/2024 | 7.11% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
05/28/2024 | 7.11% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
05/24/2024 | 7.11% | HC Wainwright & Co. | $113 → $113 | Reiterates | Buy → Buy | |||
05/14/2024 | -5.21% | Evercore ISI Group | → $100 | Initiates | → In-Line | |||
05/08/2024 | 7.11% | HC Wainwright & Co. | $107 → $113 | Maintains | Buy | |||
05/07/2024 | -7.11% | TD Cowen | $95 → $98 | Maintains | Hold | |||
05/07/2024 | 15.64% | BMO Capital | $123 → $122 | Maintains | Outperform | |||
04/17/2024 | 1.42% | HC Wainwright & Co. | $107 → $107 | Reiterates | Buy → Buy | |||
03/27/2024 | -4.27% | UBS | $110 → $101 | Maintains | Neutral | |||
03/22/2024 | -14.69% | JP Morgan | $99 → $90 | Maintains | Underweight | |||
03/21/2024 | 62.09% | Canaccord Genuity | $171 → $171 | Reiterates | Buy → Buy | |||
03/21/2024 | 16.59% | BMO Capital | $127 → $123 | Maintains | Outperform | |||
02/28/2024 | -5.21% | Goldman Sachs | $113 → $100 | Maintains | Neutral | |||
02/23/2024 | 62.09% | Canaccord Genuity | $171 → $171 | Reiterates | Buy → Buy | |||
02/23/2024 | 20.38% | BMO Capital | → $127 | Initiates | → Outperform | |||
02/21/2024 | 62.09% | Canaccord Genuity | $171 → $171 | Reiterates | Buy → Buy | |||
02/20/2024 | 62.09% | Canaccord Genuity | $168 → $171 | Maintains | Buy | |||
01/23/2024 | 1.42% | HC Wainwright & Co. | $133 → $107 | Maintains | Buy | |||
12/01/2023 | -6.16% | JP Morgan | $106 → $99 | Downgrade | Neutral → Underweight | |||
11/27/2023 | 26.07% | HC Wainwright & Co. | → $133 | Reiterates | Buy → Buy | |||
11/14/2023 | 26.07% | HC Wainwright & Co. | $180 → $133 | Maintains | Buy | |||
11/08/2023 | 5.21% | Morgan Stanley | $110 → $111 | Maintains | Equal-Weight | |||
10/17/2023 | 4.27% | Morgan Stanley | $116 → $110 | Maintains | Equal-Weight | |||
10/16/2023 | 5.21% | HSBC | $124 → $111 | Downgrade | Buy → Hold | |||
08/28/2023 | 70.62% | HC Wainwright & Co. | → $180 | Reiterates | Buy → Buy | |||
08/10/2023 | 70.62% | HC Wainwright & Co. | $181 → $180 | Maintains | Buy | |||
08/08/2023 | 9.95% | Morgan Stanley | $119 → $116 | Maintains | Equal-Weight | |||
08/01/2023 | 12.8% | Morgan Stanley | $119 → $119 | Reiterates | Equal-Weight → Equal-Weight | |||
07/31/2023 | 12.8% | Morgan Stanley | $119 → $119 | Reiterates | Equal-Weight → Equal-Weight | |||
07/24/2023 | 12.8% | Morgan Stanley | $119 → $119 | Reiterates | Equal-Weight → Equal-Weight | |||
07/17/2023 | 12.8% | Morgan Stanley | $119 → $119 | Reiterates | Equal-Weight → Equal-Weight | |||
07/14/2023 | 17.54% | HSBC | → $124 | Initiates | → Buy | |||
07/11/2023 | 12.8% | Morgan Stanley | $124 → $119 | Maintains | Equal-Weight | |||
06/26/2023 | 17.54% | Morgan Stanley | $124 → $124 | Reiterates | Equal-Weight → Equal-Weight | |||
06/20/2023 | 17.54% | Morgan Stanley | → $124 | Reiterates | Equal-Weight → Equal-Weight | |||
06/16/2023 | 92.42% | Canaccord Genuity | $203 → $203 | Reiterates | Buy → Buy | |||
06/12/2023 | 17.54% | Morgan Stanley | → $124 | Reiterates | → Equal-Weight | |||
06/09/2023 | 71.56% | HC Wainwright & Co. | → $181 | Reiterates | → Buy | |||
06/01/2023 | 71.56% | HC Wainwright & Co. | $198 → $181 | Maintains | Buy | |||
05/23/2023 | 87.68% | HC Wainwright & Co. | $210 → $198 | Maintains | Buy | |||
05/18/2023 | 13.74% | Deutsche Bank | $135 → $120 | Maintains | Hold |
FAQ
Quel est le cours indicatif de l'action BioNTech (BNTX) ?
Le dernier objectif de prix pour BioNTech (NASDAQ:BNTX) a été rapporté par JP Morgan le octobre 23, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $120.00 s'attendant à ce que BNTX se rise dans les 12 prochains mois (un possible changement de 13.74% upside). 38 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour BioNTech (BNTX) ?
La dernière note d'analyste pour BioNTech (NASDAQ:BNTX) a été fournie par JP Morgan, et BioNTech maintenu leur note neutral.
Quand a eu lieu la dernière mise à niveau pour BioNTech (BNTX) ?
La dernière amélioration pour BioNTech SE a eu lieu le novembre 19, 2024 lorsque Evercore ISI Group a augmenté leur objectif de prix à $125. Evercore ISI Group avait précédemment an in-line pour BioNTech SE.
Quand a eu lieu la dernière dégradation pour BioNTech (BNTX) ?
La dernière réduction pour BioNTech SE a eu lieu le décembre 1, 2023 lorsque JP Morgan a changé leur objectif de prix de $106 à $99 pour BioNTech SE.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour BioNTech (BNTX) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de BioNTech, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour BioNTech a été déposée le octobre 23, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 23, 2026.
La note d'analyste pour BioNTech (BNTX) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de BioNTech (BNTX) était un maintenu avec un objectif de prix de $121.00 à $120.00. Le prix actuel de BioNTech (BNTX) est de $105.50, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.